{"nctId":"NCT02510014","briefTitle":"Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder","startDateStruct":{"date":"2015-07-27","type":"ACTUAL"},"conditions":["Opioid Use Disorder","Opioid-related Disorders"],"count":775,"armGroups":[{"label":"Roll-over Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: SUBOXONE sublingual film","Drug: RBP-6000"]},{"label":"De Novo Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: SUBOXONE sublingual film","Drug: RBP-6000"]}],"interventions":[{"name":"SUBOXONE sublingual film","otherNames":["SUBOXONE","buprenorphine"]},{"name":"RBP-6000","otherNames":["Atrigel buprenorphine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nDe novo subjects:\n\n* Seeking treatment for opioid use disorder (OUD) and for the previous 3 months meet the Diagnostic and Statistical Manual 5 (DSM-5) criteria for moderate or severe OUD\n* Appropriate candidate for opioid partial-agonist treatment\n* BMI between 18 and 35, inclusive\n\nRoll-over subjects:\n\n* Completed RB-US-13-0001\n\nExclusion Criteria:\n\nDe novo subjects:\n\n* Current diagnosis, other than OUD, requiring chronic opioid treatment\n* Current substance use disorder with regard to substances other than opioids, cocaine, cannabis, tobacco or alcohol\n* Received medication-assisted treatment for OUD in the 90 days prior to informed consent\n* Use (within past 30 days prior to informed consent) or positive urine drug screen (UDS) at screening for barbiturates, benzodiazepines,methadone or buprenorphine\n* Treatment for OUD required by court order\n* History of recent suicidal ideation or attempt\n\nRoll over subjects:\n\n* Experienced major protocol deviations or adverse events in RB-US-13-0001 which could potentially compromise subject safety\n* Discontinued early from study RB-US-13-0001","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period","description":"TEAE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= a marked limitation in activity. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent one of the outcomes listed in this definition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"302","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"172","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage Change From Baseline to End of Study (Weeks 25 and 49) in Vital Signs","description":"Vital signs include\n\n* systolic blood pressure (mmHg)\n* diastolic blood pressure (mmHg)\n* respiratory rate (breaths/minute)\n* weight (kg)\n* body mass index (kg/m\\^2)\n* waist-to-hip ratio\n\nBaseline is defined as the last non-missing value prior to subcutaneous injection of RBP-6000 on Day 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"11.69"},{"groupId":"OG001","value":"1.3","spread":"11.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"13.97"},{"groupId":"OG001","value":"1.6","spread":"12.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"11.11"},{"groupId":"OG001","value":"1.0","spread":"11.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"10.651"},{"groupId":"OG001","value":"-0.94","spread":"6.497"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"10.657"},{"groupId":"OG001","value":"-0.93","spread":"6.507"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.828","spread":"11.1698"},{"groupId":"OG001","value":"1.015","spread":"8.1150"}]}]}]},{"type":"PRIMARY","title":"Shifts in Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Most Severe Assessment During the Treatment Period","description":"The C-SSRS asks questions of study participants regarding whether they had suicidal ideation and/or suicidal behavior since the last visit using the electronic version of the scale. Only the most severe assessment is reported in this summary. Participants who experienced suicidal ideation and suicidal behavior are only summarized in the suicidal behavior since behavior is more severe than ideation.\n\nC-SSRS baseline version was completed during the screening visit. C-SSRS 'since-last-visit' version was completed weekly for the first month and at least every month until the end of the study.\n\nShift table category titles are structured as: baseline category/treatment category. The category 'No Suicidal Ideation or Behaviour' has been abbreviated as 'No Suicidal I or B'.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null},{"groupId":"OG001","value":"252","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Worst Local Injection Site Pain From Injections as Measured by Participant-Reported Visual Analog Scale (VAS)","description":"Injection site pain as measured by participant-reported VAS. The participant-reported VAS for injection site pain was measured on a 100 mm scale with 'no pain' at 0 mm and 'strongest pain ever' at 100 mm (total scale of 0-100). Participants marked where along the scale reflected their localized injection pain.\n\nThe injection site pain VAS scores were obtained (after the completion of the injection) within 1 minute and at 5, 10, 15, 30 and 60 minutes (+- 5 minutes). The timing of the injection site pain VAS should have been measured from the end of the injection.\n\nData represents the worst pain recorded for each participant across all injections and all VAS records. The mean value is presented.\n\nDe Novo subjects were given injections on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281 and 309.\n\nRoll-over subjects were given injections on Days 1, 29, 57, 85, 113, 141.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":"29.86"},{"groupId":"OG001","value":"33.5","spread":"31.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":"31.98"},{"groupId":"OG001","value":"32.7","spread":"31.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":"32.14"},{"groupId":"OG001","value":"30.2","spread":"32.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.6","spread":"32.86"},{"groupId":"OG001","value":"31.3","spread":"31.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"30.96"},{"groupId":"OG001","value":"32.2","spread":"31.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":"31.89"},{"groupId":"OG001","value":"30.5","spread":"30.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":"32.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"30.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":"33.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":"33.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"30.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":"28.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Clinical Opiate Withdrawal Scale (COWS) at End of Study (Weeks 25 and 49)","description":"COWS is an 11-item instrument used to assess signs and symptoms of opioid withdrawal. The score is the sum of the responses for a total range of 0-48. The COWS is commonly used by clinicians treating patients with buprenorphine to monitor the severity of withdrawal. COWS scores below 5 are considered not indicative of withdrawal. Scores from 5 to 12 are considered mild withdrawal; from 13 to 24 moderate withdrawal; 25 to 36 moderately severe withdrawal, and 37-48 severe withdrawal. Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.43"},{"groupId":"OG001","value":"1.5","spread":"1.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.61"},{"groupId":"OG001","value":"-0.3","spread":"2.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Subjective Opiate Withdrawal Scale (SOWS) at End of Study (Weeks 25 and 49)","description":"The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the participant rates on a scale of 0 (not at all) to 4 (extremely) for a full scale of 0 (no withdrawal symptoms) to 64 (extreme withdrawal symptoms). Negative change from baseline values indicate a lessening of withdrawal symptoms.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"5.27"},{"groupId":"OG001","value":"2.8","spread":"5.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"6.63"},{"groupId":"OG001","value":"1.1","spread":"7.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"5.05"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Opioid Craving Visual Analog Scale (VAS) at End of Study (Weeks 25 and 49)","description":"The opioid craving scale was a 100 mm scale with 'no craving' indicated by 0 mm and 'strongest craving ever' indicated by 100 mm. Participants marked where along the scale reflected their craving for opioids.\n\nBaseline was defined as the last non-missing value prior to subcutaneous injection on Day 1. Baseline value is reported as an observed actual value. Weeks 25 and 49 represent change from baseline values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"10.59"},{"groupId":"OG001","value":"4.4","spread":"9.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"16.19"},{"groupId":"OG001","value":"4.2","spread":"16.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"10.83"}]}]}]},{"type":"SECONDARY","title":"Cumulative Distribution Function (CDF) of the Percentage Abstinence Collected From Week 1 Through End of Study (Weeks 25 and 49)","description":"Participants' self-reported illicit opioid drug use from the timeline followback (TLFB) interview and results from the urine drug screens (UDS) for opioids were combined into a single endpoint. Opioids assessed included codeine, hydrocodone, hydromorphone, methadone, morphine, opiates, oxycodone, and oxymorphone (by UDS) and amphetamine/methadone, buprenorphine, methadone, and opioids in the TLFB.\n\nData represent the count of participants at various percentage abstinence levels. Abstinence was defined as urine samples being negative for opioids AND negative self-reports (obtained from Timeline Followback (TLFB) interviews) for illicit opioid use. The endpoint was based on visits in which paired urine samples and self-reports were expected for each subject as specified in the schedule of events. All missing reports for opioids were considered nonnegative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"412","spread":null},{"groupId":"OG001","value":"257","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"315","spread":null},{"groupId":"OG001","value":"206","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"278","spread":null},{"groupId":"OG001","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"166","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"132","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":412},"commonTop":["Constipation","Nausea","Injection site pain","Insomnia","Headache"]}}}